Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid
Authors:
Open Access
- 28 January 2022
- journal article
- review article
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 37 (6) , 1745-1756
Abstract
Whereas significant strides have been made in the treatment of lysosomal storage diseases (LSDs), the neuronopathy associated with these diseases remains impervious mainly because of the blood-brain barrier (BBB), which prevents delivery of large molecules to the brain. However, 100 years of research on the BBB since its conceptualization have clarified many of its functional and structural characteristics, spurring recent endeavors to deliver therapeutics across it to treat central nervous system (CNS) disorders, including neuronopathic LSDs. Along with the BBB, the cerebrospinal fluid (CSF) also functions to protect the microenvironment of the CNS, and it is therefore deeply involved in CNS disorders at large. Recent research aimed at developing therapeutics for neuronopathic LSDs has uncovered a number of critical roles played by the CSF that require further clarification. This review summarizes the most up-to-date understanding of the BBB and the CSF acquired during the development of therapeutics for neuronopathic LSDs, and highlights some of the associated challenges that require further research.Keywords
This publication has 82 references indexed in Scilit:
- Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain BarrierScience Translational Medicine, 2013
- Glycemic Control and Chronic Dosing of Rhesus Monkeys with a Fusion Protein of Iduronidase and a Monoclonal Antibody Against the Human Insulin ReceptorDrug Metabolism and Disposition, 2012
- A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid βScience Translational Medicine, 2012
- Therapeutic Potential of Intracerebroventricular Replacement of Modified Human β-Hexosaminidase B for GM2 GangliosidosisMolecular Therapy, 2011
- Drug transport in brain via the cerebrospinal fluidFluids and Barriers of the CNS, 2011
- Recent insights into a new hydrodynamics of the cerebrospinal fluidBrain Research Reviews, 2011
- The formation of cerebrospinal fluid: Nearly a hundred years of interpretations and misinterpretationsBrain Research Reviews, 2010
- Structure and function of the blood–brain barrierNeurobiology of Disease, 2010
- Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.Proceedings of the National Academy of Sciences, 1991
- FINE STRUCTURAL LOCALIZATION OF A BLOOD-BRAIN BARRIER TO EXOGENOUS PEROXIDASEJournal of Cell Biology, 1967